Room: 2C/3C Mile High Ballroom
Organizers: David Huang, Philip Rosenfeld,
Moderators: Carmen Puliafito, James Fujimoto
Participating in the Technology panel: David Huang, Yoshiaki Yasuno, R...
Dr. Carmen A. Puliafito was appointed dean and holder of the May S. and John Hooval Dean’s Chair at the Keck School of Medicine of USC effective November 1, 2007. He also serves as a professor of ophthalmology and health management. Before joining USC, Puliafito was chair of the Department of Ophthalmology and director of the Bascom Palmer Eye Institute at the University of Miami’s Miller School of Medicine. There, he oversaw a twofold increase in faculty size, a rise from 34th to 14th in National Institutes of Health funding within a three-year span, and the reclaiming of the top position in U.S. News & World Report’s eye-hospital rankings from the Wilmer Eye Institute at Johns Hopkins University. He also guided fundraising and the development of a $22 million, seven-acre, state-of-the-art campus in Palm Beach Gardens. Puliafito earned his medical degree, magna cum laude, at Harvard Medical School. Following a residency and fellowships at the Massachusetts Eye and Ear Infirmary (MEEI), he served on the faculties of both Harvard and MIT and founded MEEI’s Morse Laser Center and Laboratory. He went on to build an eye program at Tufts University, where he became founding director of the New England Eye Center. An internationally recognized leader in ophthalmic laser technology, Puliafito has served as president of the American Society for Laser Medicine and Surgery and as trustee and president of the Association for Research in Vision and Ophthalmology, the world’s largest eye-research organization. He holds two U.S. patents and has written more than 120 peer-reviewed scientific articles as well as six books. In addition to his MD from Harvard University, Puliafito has an MBA from the Wharton School of the University of Pennsylvania.
OCT has revolutionized the treatment of eye disease on a global basis and it is now routinely used to make clinical decisions in treating patients with blinding eye diseases...I’ve been honored to be part of the team that created this technology and to know our creation has improved diagnosis and treatment for millions of eye patients around the world.In USC Roski Eye Institute Joins the ARVO Campaign to Promote the Impact of Optical Coherence Tomography, USC Clinician/Scientist one of OCT Inventors
The USC Eye Institute is pioneering the development of novel treatments for eye diseases that cause vision loss and contributing critical scientific knowledge to advance the field of ophthalmology.In USC Eye Institute Adds 12 Faculty Physician Scientists in 2014
OCT has revolutionized the treatment of eye disease on a global basis, and it is now routinely used to make clinical decisions about treating patients with blinding diseases such as macular degeneration, diabetic retinopathy and glaucoma.In Cirrus HD-OCT Record Number of 10,000 Installations and Prestigious Award for OCT Inventors
OCT is a case study in the power of collaboration between engineering and medicine in the development of new technologies that can dramatically improve patient care...I am deeply honored to receive the award and proud to have been at the forefront of such an important contribution to the field of vision medicine.In Puliafito honored with international Vision Award in Portugal
We can evaluate underlying pathology and monitor disease response, retinal thickness, cystoid macular edema, vitreoretinal traction and track subretinal fluid.In Spectral domain OCT useful as research tool, clinical adjunct
This last point may be a little counterintuitive. The patients that need the most careful macular exam, the most careful scrutiny with OCT, are the patients with relatively good vision that you're considering operating on because they actually in many ways have the most to lose by the cataract operation.In Surgeon suggests using OCT for preop cataract evaluation to protect patient, physician